Overall survival reached 88.8% for older patients receiving radiotherapy after breast-conserving surgery, compared to 82.3% for those who did not, according to a study published in November 2026.
The research, titled Adjuvant Radiotherapy and Survival After Breast-Conserving Surgery in Women Aged ≥70 Years with Hormone Receptor–Positive T1–2N0M0 Breast Cancer: A Propensity Score–Matched SEER Study and published in the International Journal of Women’s Health, examined population-based data to evaluate postoperative treatment outcomes. Linyue Sun, Xinian Jiang, Ziyu Chen and their co-authors evaluated data from 8,934 patients diagnosed between 2016 and 2017.
Following propensity score matching across 2,591 pairs, the authors reported a cumulative incidence of breast cancer death at 1.33% with radiotherapy versus 2.80% without it. PubMed indexed the study on November 17, 2026, noting that the findings showed lower all-cause mortality associated with the treatment.
Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, cautioned against using age alone to omit treatment. Writing on LinkedIn, Mokbel pointed out that out of 718 deaths in the matched cohort, 598 were confirmed to come from other causes.
“How much of that survival difference can we attribute to radiotherapy?” Mokbel asked on LinkedIn. The database lacked records on patient frailty, underlying health conditions, and adherence to endocrine therapy, leaving unmeasured variables that matching methods cannot fully resolve.
By contrast, the randomized PRIME II trial found that at 10 years, local recurrence reached 9.5% without radiotherapy compared to 0.9% with it, while overall survival remained near 81% in both groups. Mokbel said that shared decisions should incorporate tumor features, life expectancy, and a patient’s preferences regarding additional operations.
The investigators examined overall survival using Kaplan-Meier and Cox methods according to PubMed. Competing mortality was addressed using cumulative incidence functions and multivariable Fine-Gray regression as reported in the International Journal of Women’s Health.
Fine-Gray regression yielded an sHR of 0.442 with a 95% confidence interval from 0.295 to 0.662. Radiotherapy was further associated with lower all-cause mortality and a lower cause-specific hazard of breast cancer death.
The study recorded a hazard ratio for all-cause mortality of 0.572 with a 95% confidence interval spanning from 0.492 to 0.664. The cause-specific hazard ratio for breast cancer death reached 0.414 alongside a 95% confidence interval of 0.276 to 0.619.
Inverse probability of treatment weighting and propensity score matching were employed to address measured confounding. Linyue Sun and co-authors published these statistical evaluations in November 2026.
Kefah Mokbel brings extensive specialist expertise to his interpretation of breast cancer data. Serving as the chair of breast cancer surgery and the multidisciplinary breast cancer program at the London Breast Institute of the Princess Grace Hospital, Mokbel has built a prominent clinical and research career.
He was appointed Professor (Honorary) of Breast Cancer Surgery at Brunel University London in 2002 in recognition of his contributions to breast cancer research, and he has published over 400 papers in medical literature.
“In my practice, I would offer omission as an option to a woman who meets the trial criteria,” Mokbel said, adding that clinicians should explain the expected reduction in local recurrences over a decade.
Related reading